Drug intelligence / Profile preview

eztilimab

Development stage: Phase 1
Lead developer: Tizona Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Eztilimab is a first-in-class anti-CD39 antibody developed for cancer immunotherapy. It targets the adenosine pathway, a mechanism utilized by tumors to evade the immune system. Initially developed by Tizona Therapeutics, it entered into a global collaboration with AbbVie for research, development, and commercialization. Subsequently, Tizona Therapeutics licensed eztilimab to MacroGenics for further development.

Targets

ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1)

Beyond the preview

Go deeper on eztilimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eztilimab.

Explore the full profile